BMY - Bristol-Myers Squibb - net sales from continuing operations of $5.4 billion increased 33% year-over-year

Bristol-Myers Squibb (BMY) will release first-quarter results on April 24. BMY declared a quarterly dividend of 31 cents per share in early March . With a yield of 5.6%, Bristol-Myers Squibb is an industry standout as very few drug companies pay a dividend. The company sports solid growth in addition to income. In late January, Bristol-Myers reported net sales from continuing operations of $5.4 billion increased 33% year-over-year.

Full Analysis

Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.

The company recently announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA(R) (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA).

"In a JIA clinical trial, ORENCIA provided meaningful and sustained improvements in this patient population across three major sub-types of JIA through one year," said Edward H. Giannini, M.Sc., Dr.P.H., Professor of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, OH.

Income

BMY declared a quarterly dividend of 31 cents per share in early March. The company stated that the dividend will be payable on May 1, 2008, to stockholders of record as of close of business on April 4, 2008. Offering a dividend yield of 5.6%, Bristol-Myers Squibb is an industry standout as very few drug companies pay a dividend.

Growth

The company sports solid growth in addition to income. In late January, Bristol-Myers reported fourth-quarter and full-year results. Fourth-quarter earnings of 33 cents, which topped the previous year’s result. Quarterly net sales from continuing operations of $5.4 billion increased 33% year-over-year.

The release of first-quarter results is scheduled for April 24, 2008.

Content Courtesy: Zacks Investment Research

#1 Ranked Stocks Highlight Archive
To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions.

| Blog Home| VitalStocks Home